CRESCENT BIOPHARMA, INC.
CBIONext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for CBIO. That does not mean none is planned.
Get an email about CBIO's next catalysts
Track CRESCENT BIOPHARMA (CBIO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
CBIO Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.72 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
CR-002
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
CR-001
Locally Advanced / Metastatic Solid Tumors
Gemcitabin
Locally Advanced / Metastatic Solid Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CR-002 | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | - | - |
CR-001 | Phase 2 | Locally Advanced / Metastatic Solid Tumors | - | - |
Gemcitabin | Phase 2 | Locally Advanced / Metastatic Solid Tumors | - | - |
Frequently asked questions
What is in CRESCENT BIOPHARMA, INC.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in CRESCENT BIOPHARMA, INC.'s (CBIO) pipeline across Phase 2. Its lead program is CR-001 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CRESCENT BIOPHARMA, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for CRESCENT BIOPHARMA, INC. (CBIO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CBIO biotech catalysts?→
Add CBIO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CRESCENT BIOPHARMA, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.